PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
223 hedge funds and large institutions have $1.23B invested in PDL BioPharma, Inc. in 2014 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 81 increasing their positions, 78 reducing their positions, and 26 closing their positions.
8% more capital invested
Capital invested by funds: $1.14B → $1.23B (+$88.4M)
4% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 78
3% less funds holding
Funds holding: 231 → 223 (-8)
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
55% less call options, than puts
Call options by funds: $2.02M | Put options by funds: $4.49M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$60.1M |
| 2 |
LCP
Lombardia Capital Partners
Pasadena,
California
|
+$10.8M |
| 3 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
+$8.36M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$8.08M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$7.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QI
QS Investors
New York
|
-$17.6M |
| 2 |
Renaissance Technologies
New York
|
-$15.6M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$7.22M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$6.59M |
| 5 |
Morgan Stanley
New York
|
-$6.37M |
PDLI Hedge Fund Activity: Q4 2014 in Review
223 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q4 2014, worth a combined $1.23B — up 7.8% from $1.14B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of PDLI and 21 opened new positions — a net loss of 5 holders — while 78 trimmed existing stakes and 81 added.
The largest buyer was First Trust Advisors, adding an estimated $60.1M. The largest seller was QS Investors, cutting an estimated $17.6M.
- 223 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q4 2014, down from 231 in Q3 2014.
- Funds reported $1.23B of PDL BioPharma, Inc. stock for Q4 2014, up 7.8% quarter-over-quarter.
- 21 funds opened new PDL BioPharma, Inc. positions in Q4 2014 and 26 closed out, a net change of -5 holders.
- The largest PDL BioPharma, Inc. buyer in Q4 2014 was First Trust Advisors, an estimated $60.1M added.
- The largest PDL BioPharma, Inc. seller in Q4 2014 was QS Investors, an estimated $17.6M sold.
Based on aggregated 13F filings for Q4 2014.